Industry
Biotechnology
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 7:24 am
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 10:32 am
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 8:29 pm
Portfolio Pulse from Avi Kapoor
June 05, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:40 pm
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Newsdesk
February 28, 2024 | 2:21 pm
Portfolio Pulse from Benzinga Newsdesk
January 23, 2024 | 5:06 pm
Portfolio Pulse from Benzinga Newsdesk
January 23, 2024 | 9:34 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.